Flow-cytometric analysis of MM cell viability after 4 hours revealed that lenalidomide enhanced the PBMC-mediated killing of both lenalidomide-sensitive and lenalidomide-resistant cell lines (Figure 5B), with increased granzyme B release in the co-culture system (Figure 5C). The gene discussed is GZMB; the disease is Miyoshi myopathy.